{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(1)"],"submitter":["Kim WJ"],"funding":["Chong Kun Dang Bio Co. Ltd"],"pubmed_abstract":["The gut microbiota plays a pivotal role in metabolic disorders, notably type 2 diabetes mellitus (T2DM). In this study, we investigated the synergistic potential of combining the effects of <i>Bifidobacterium longum</i> NBM7-1 (CKD1) with anti-diabetic medicines, Lobeglitazone<sup>Ⓡ</sup> (LO), Sitagliptin<sup>Ⓡ</sup> (SI), and Metformin<sup>Ⓡ</sup> (Met), to alleviate hyperglycemia in a diabetic mouse model. CKD1 effectively mitigated insulin resistance, hepatic steatosis, and enhanced pancreatic β-cell function, as well as fortifying gut-tight junction integrity. In the same way, SI-CKD1 and Met- CKD1 synergistically improved insulin sensitivity and prevented hepatic steatosis, as evidenced by the modulation of key genes associated with insulin signaling, β-oxidation, gluconeogenesis, ad"],"journal":["Gut microbes"],"pagination":["2319889"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10896159"],"repository":["biostudies-literature"],"pubmed_title":["<i>B. longum</i> CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice."],"pmcid":["PMC10896159"],"pubmed_authors":["Kim WJ","Lee C","Kim TY","Kim H","Han G","Kim K","Huh CS","Choi Y","Shin CH","Park SY","Kil BJ","Kim M"],"additional_accession":[]},"is_claimable":false,"name":"<i>B. longum</i> CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice.","description":"The gut microbiota plays a pivotal role in metabolic disorders, notably type 2 diabetes mellitus (T2DM). In this study, we investigated the synergistic potential of combining the effects of <i>Bifidobacterium longum</i> NBM7-1 (CKD1) with anti-diabetic medicines, Lobeglitazone<sup>Ⓡ</sup> (LO), Sitagliptin<sup>Ⓡ</sup> (SI), and Metformin<sup>Ⓡ</sup> (Met), to alleviate hyperglycemia in a diabetic mouse model. CKD1 effectively mitigated insulin resistance, hepatic steatosis, and enhanced pancreatic β-cell function, as well as fortifying gut-tight junction integrity. In the same way, SI-CKD1 and Met- CKD1 synergistically improved insulin sensitivity and prevented hepatic steatosis, as evidenced by the modulation of key genes associated with insulin signaling, β-oxidation, gluconeogenesis, ad","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan-Dec","modification":"2026-05-09T03:10:34.409Z","creation":"2025-05-29T21:39:01.639Z"},"accession":"S-EPMC10896159","cross_references":{"pubmed":["38391178"],"doi":["10.1080/19490976.2024.2319889"]}}